# US 5,705,157 A · Methods of treating cancerous cells with anti-receptor antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,705,157 A
- Document ID: US5705157A
- Status: Granted
- Kind: A
- Application number: 08/347,018
- Filed: 1994-11-30
- Granted: 1998-01-06
- Earliest claimed: 1989-07-27
- Assignees: The Trustees of the University of Pennsylvania
- Inventors: Mark I. Greene
- Web page: https://patentgrep.com/patent/US5705157A

## CPC

- C07K 16/32: against translation products of oncogenes
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides methods and therapeutic compositions for treatment of mammalian tumors wherein the cells of such tumor express both epidermal growth factor receptor and p185neu, p185c-neu or a homologue of p185neu or p185c-neu and the epidermal growth factor. At least one antibody specific for epidermal growth factor receptor, monoclonal antibody 425, and at least one antibody specific for p185neu, p185c-neu or a homologue of p185neu or p185c-neu, monoclonal antibody 7.16.4, are administered to the mammal in an amount effective to reduce tumor growth.

## Claims

### Claim 1

A method of treating mammalian tumors wherein the cells of such tumor express both 1) epidermal growth factor receptor and 2) p185neu, p185c-neu or a homologue of p185neu or p185c-neu, said method comprising
administering to a mammal having such a tumor at least one antibody specific for epidermal growth factor receptor and at least one antibody specific for p185neu, p185c-neu or a homologue of p185neu or p185c-neu or a homologue in an amount effective to reduce tumor growth, wherein said antibody specific for epidermal growth factor receptor is Mab425 and said antibody specific for p185neu, p185c-neu or a homologue of p185neu or p185c-neu is Mab 7.16.4.

### Claim 2 (depends on 1)

The method of claim 1 wherein each of said antibodies is conjugated with a cytotoxic molecule.

### Claim 3 (depends on 1)

The method of claim 1 wherein each of said antibodies is conjugated with a radioactive molecule.

### Claim 4

A therapeutic composition for treatment of a mammalian cancer tumor having cells which express both epidermal growth factor receptor and p185neu, p185c-neu or a homologue of p185neu or p185c-neu comprising
at least one antibody specific for p185neu, p185c-neu or a homologue of p185neu or p185c-neu;
at least one antibody specific for epidermal growth factor receptor; and
a pharmaceutically acceptable carrier or diluent, wherein said antibody specific for epidermal growth factor receptor is Mab425 and said antibody specific for p185neu, p185c-neu or a homologue of p185neu or p185c-neu is Mab 7.16.4.

### Claim 5 (depends on 4)

The composition of claim 4 wherein each of said antibodies is conjugated with a cytotoxic molecule.

### Claim 6 (depends on 4)

The composition of claim 4 wherein each of said antibodies is conjugated with a radioactive molecule.